 |
Article Review/Hyperlink |
Packer M, Colucci WS, Sackner-Bernstein JD, et al for the PRECISE Study Group
Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure
Circulation (Dec) 94:2793-2799 1996
Carvedilol is a third generation, vasodilating beta-blocker. In the December 1 issue of Circulation, results of 3 trials using carvedilol in CHF patients are published. In the cited paper, from the PRECISE Study group, patients with moderate to severe heart failure were studied. Carvedilol or placebo was added to standard theray, which included diuretics, digoxin, and/or an ACE inhibitor. Carvedilol Rx was associated with a reduced progression to a combined morbidity/mortality endpoint and better ultimate NYHA functional class. (jtd)
The text of the original abstract is available from the AHA at: this site .
The text of the a related abstract by Colucci describing results of carvedilol therapy in mild CHF is available from the AHA at: this site .
| Related Folders: |
|
|
